EA201000617A1 - Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей - Google Patents

Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей

Info

Publication number
EA201000617A1
EA201000617A1 EA201000617A EA201000617A EA201000617A1 EA 201000617 A1 EA201000617 A1 EA 201000617A1 EA 201000617 A EA201000617 A EA 201000617A EA 201000617 A EA201000617 A EA 201000617A EA 201000617 A1 EA201000617 A1 EA 201000617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
antagonist
treatment
inhibitor
purin
Prior art date
Application number
EA201000617A
Other languages
English (en)
Inventor
Робин Алек Фэрхёрст
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201000617A1 publication Critical patent/EA201000617A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описано лекарственное средство, включающее по отдельности или совместно компонент (А), который представляет собой агонист аденозинового рецептора А, определенный в описании; и компонент (В), который представляет собой одно или большее количество соединений, выбранных из группы, включающей: (i) кортикостероид, (ii) агонист бета-2 адренорецептора, (iii) антимускариновое средство, (iv) антагонист A, (v) антигистамин, (vi) ингибитор каспазы, (vii) ингибитор ENaC, (viii) антагонист LTB4, (ix) антагонист LTD4, (х) ингибитор серинпротеазы, (xi) ингибитор PDE4 и (xii) двойной агонист бета-2 адренорецептора/мускариновый антагонист, предназначенное для одновременного, последовательного или раздельного введения при лечении воспалительного или обструктивного заболевания дыхательных путей.
EA201000617A 2007-10-17 2008-10-15 Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей EA201000617A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118721 2007-10-17
PCT/EP2008/063869 WO2009050198A2 (en) 2007-10-17 2008-10-15 Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases

Publications (1)

Publication Number Publication Date
EA201000617A1 true EA201000617A1 (ru) 2010-10-29

Family

ID=39185790

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000617A EA201000617A1 (ru) 2007-10-17 2008-10-15 Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей

Country Status (21)

Country Link
US (1) US20090181934A1 (ru)
EP (1) EP2211865A2 (ru)
JP (1) JP2011500630A (ru)
KR (1) KR20100075925A (ru)
CN (1) CN101827596A (ru)
AR (1) AR068879A1 (ru)
AU (1) AU2008313788A1 (ru)
BR (1) BRPI0818005A2 (ru)
CA (1) CA2702942A1 (ru)
CL (1) CL2008003057A1 (ru)
CR (1) CR11341A (ru)
CU (1) CU20100065A7 (ru)
EA (1) EA201000617A1 (ru)
IL (1) IL204723A0 (ru)
MA (1) MA31796B1 (ru)
MX (1) MX2010004252A (ru)
PE (1) PE20091392A1 (ru)
TN (1) TN2010000168A1 (ru)
TW (1) TW200927129A (ru)
WO (1) WO2009050198A2 (ru)
ZA (1) ZA201002336B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2013211T3 (pl) 2006-04-21 2012-08-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A2A
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
JP2011500631A (ja) * 2007-10-17 2011-01-06 ノバルティス アーゲー アデノシンａ１受容体リガンドとしてのプリン誘導体
CN104321057B (zh) 2012-04-20 2016-09-14 Ucb医药有限公司 用于治疗帕金森病的方法
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2013211T3 (pl) * 2006-04-21 2012-08-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A2A
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
TW200927129A (en) 2009-07-01
ZA201002336B (en) 2011-04-28
AR068879A1 (es) 2009-12-09
KR20100075925A (ko) 2010-07-05
CR11341A (es) 2010-05-06
PE20091392A1 (es) 2009-10-14
US20090181934A1 (en) 2009-07-16
CN101827596A (zh) 2010-09-08
WO2009050198A2 (en) 2009-04-23
CA2702942A1 (en) 2009-04-23
MA31796B1 (fr) 2010-10-01
CU20100065A7 (es) 2011-10-05
IL204723A0 (en) 2010-11-30
JP2011500630A (ja) 2011-01-06
CL2008003057A1 (es) 2009-06-26
MX2010004252A (es) 2010-04-30
WO2009050198A3 (en) 2009-09-11
EP2211865A2 (en) 2010-08-04
BRPI0818005A2 (pt) 2015-04-14
AU2008313788A1 (en) 2009-04-23
TN2010000168A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
EA201000617A1 (ru) Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
BRPI0617673C1 (pt) composições de inibidores de fosfodiesterase do tipo iv
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
JP2008528469A5 (ru)
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2007126964A3 (en) Kinase inhibitors
NO20065483L (no) Kombinasjoner omfattende antimuskarinmidler og PDE4-inhibitorer
BRPI0509086A (pt) uso de inibidores de pde iii para redução do tamanho do coração em mamìferos sofrendo de parada cardìaca
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
WO2009045309A3 (en) Use of v2 receptor antagonists in combination with vasopressinergic agonists
RU2011111117A (ru) Лечение аутоиммунных заболеваний
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2008012338A3 (en) Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions